{"id":"W3193792809","doi":"10.1093/noajnl/vdab118","title":"Avelumab in newly diagnosed glioblastoma","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Victoria; University of Ottawa; University of British Columbia; Ottawa Hospital; Clinique Neuro-Outaouais","funders":"Merck KGaA; EMD Serono; Pfizer","keywords":"Avelumab; Medicine; Adverse effect; Oncology; Discontinuation; Immunotherapy; Internal medicine; Immune system; Immune checkpoint; Antibody; Progression-free survival; Monoclonal antibody; Nivolumab; Immunology; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004333862,0.0003131919,0.0007907366,0.0002095556,0.0002071289,0.0002726125,0.0002643039,0.000292557,0.0004825384],"category_scores_gemma":[0.0005605133,0.0001249119,0.0003111366,0.0002663082,0.0002341318,0.0002209623,0.0002122764,0.0005972218,0.0001735301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006074616,"about_ca_system_score_gemma":0.000530895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0010184,"about_ca_topic_score_gemma":0.003015831,"domain_scores_codex":[0.9998395,0.0000496401,0.00002396111,0.00002865527,0.00002794064,0.00003026196],"domain_scores_gemma":[0.9997057,0.00006484224,0.00008878355,0.00001865274,0.00002325302,0.00009876535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04165596,0.00306078,0.3716749,0.001900973,0.0008780253,0.02515983,0.0005493552,0.00176966,0.07571286,0.0002887037,0.003816064,0.473533],"study_design_scores_gemma":[0.01015014,0.07364458,0.7808869,0.0003677326,0.001252615,0.07720062,0.0003476692,0.003837706,0.02795817,0.0005222217,0.02375628,0.00007532279],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858417,0.01264304,0.0003258492,0.000185792,0.00005391399,0.00007051292,0.00009953822,0.00001772763,0.0007618538],"genre_scores_gemma":[0.9935219,0.005098475,0.0003774334,0.0002437216,0.00007616607,0.00004301696,0.0003302079,0.000005178265,0.0003039086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0010184,"threshold_uncertainty_score":0.004407465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01260199528843592,"score_gpt":0.3007417723979693,"score_spread":0.2881397771095334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}